United States: Considerations In Demonstrating Interchangeability With A Reference Biologic Product

Dek: Sponsors should seek early discussions with FDA to ensure an effective and efficient process for demonstrating the interchangeability of a chosen biologic product.

On May 9, 2019, FDA issued final guidance, Considerations in Demonstrating Interchangeability with a Reference Product (1). This article provides a concise summary of the guidance, which is intended to assist sponsors in demonstrating that a proposed therapeutic protein product is interchangeable with a reference product for the purposes of submitting a marketing application or supplement under section 351(k) of the Public Health Service Act (PHS Act) (42 U.S.C. 262(k)) (2).

The terms interchangeable and interchangeability, as defined in section 351(i) of the PHS Act, mean that “the biological product may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product”. To date, no such interchangeable products have been approved by FDA.

Section 351(k)(4) of the PHS Act provides that, upon review of an application submitted under section 351(k) or any supplement to such application, FDA will determine that the biological product is interchangeable with the reference product if FDA determines that the information submitted in the application or the supplement is sufficient to show that the biological product “is biosimilar to the reference product” and “can be expected to produce the same clinical result as the reference product in any given patient” and that “for a biological product that is administered more than once to an individual, the risk in terms of safety or diminished efficacy of alternating or switching between use of the biological product and the reference product is not greater than the risk of using the reference product without such alternation or switch”.

Factors impacting the type and amount of data and information needed

As a general principle, FDA intends to consider the totality of the evidence on a case-by-case basis. A stepwise approach is recommended for sponsors to generate data and information. This should allow the sponsor to raise questions and address uncertainty about how to demonstrate interchangeability at each stage of product development. Due to the complexity of the products covered by the new guidance, FDA recommends that sponsors meet with the agency early and often.

The current guidance provides several factors that may impact the type and amount of data and information needed to support a demonstration of interchangeability:

  • The product’s degree of structural and functional complexity may influence the extent of clinical data needed. For example, products that act on multiple targets, or act in less-defined biological pathways, or have certain structural features that are specifically expected to impact interchangeability may require more clinical data. For more complex products, it may be important to provide data sets that include highly sensitive analytics and sequential analytical methods. These data sets can identify molecules with different combinations of attributes and provide a comprehensive assessment of the relationships between attributes.
  • Clinical experience with the reference product and comprehensive product risk assessments may also affect the data and information needed to support a demonstration of interchangeability.
  • For products that have been previously licensed and marketed as a biosimilar, some post-marketing data is typically available from post-marketing surveillance and other post-marketing studies. Without corresponding data from the switching studies, post-marketing data alone is generally not sufficient to support a demonstration of interchangeability, but it may supplement the switching studies in certain situations. Post-marketing data may also be helpful as a factor when considering what additional data must be generated to demonstrate interchangeability.

Data and information needed to support a demonstration of interchangeability

351(k)(4)(A)

To show that the product is biosimilar to a reference product, as required in section 351(k)(4)(A)(i) of the PHS Act, the sponsor can refer to its biosimilar licensure if there is one, or make a demonstration of biosimilarity, which would include, in part, a showing that the product meets the highly similar standard.

The data and information necessary to meet the section 351(k)(4)(A) standard may include: identification and analysis of critical quality attributes; analysis of the mechanism of action in each condition of use; analysis of any differences in pharmacokinetics and biodistribution in different patient populations; analysis of any differences in the immunogenicity risk in different patient populations; analysis of any differences in toxicities in each condition of use and in each patient population; and information on other factors that affect safety and efficacy.

351(k)(4)(B)

FDA will generally expect a switching study or studies to support a showing for each of the statutory criterion in section 351(k)(4)(B) of the PHS Act. Sponsors should provide a justification if they believe that a switching study is not necessary for their product. For biological products that are not intended to be administered to an individual more than once, a switching study is generally not needed, although the focus of the current guidance is protein treatments that are typically administered recurrently.

A switching study or studies should evaluate changes in treatment that result in two or more alternating exposures (switch intervals) to the proposed interchangeable product and to the reference product. Design requirements of the switching study will be determined on a case-by-case basis. An example is depicted in the May 9, 2019 guidance (1).

Study endpoints. FDA recommends that the primary endpoints in a switching study should include a comparison of pharmacokinetic (PK) and/or pharmacodynamic (PD) parameters between the switching arm and non-switching arm following the final switch. Sponsors need to demonstrate the suitability of the PK and PD assays they develop. In cases where PK and/or PD are not adequately sensitive endpoints, sponsors are expected to propose and justify selected endpoints other than PK or PD measures. In addition to PK/PD, descriptive assessments of immunogenicity and safety are also expected.

A switching study may also incorporate the evaluation of efficacy endpoints, although they are generally not as sensitive as PK/PD endpoints.

Study design and analysis. The guidance discusses several considerations in the design of a dedicated switching study: sample size, which should generally be based on PK considerations; number and duration of switches; when to sample PK, PD, and immunogenicity; and study analysis.

If a sponsor is considering a single study to show both biosimilarity and interchangeability, then an integrated two-part study design may be appropriate. After the end of the first part of the study on biosimilarity, the subjects in the reference product arm should be re-randomized for the second part of the study on interchangeability. An integrated study needs to be adequately powered to evaluate both the endpoints for biosimilarity and interchangeability.

Study population. Sponsors should provide scientific justification to demonstrate that the study population for switching studies is adequately sensitive to detect the impact of switching. FDA generally recommends that sponsors use patients in switching studies. When considering using healthy subjects, the sponsor should weigh the benefit of exposing healthy subjects to the biologic products and the risk of having them develop antibodies, which may in turn preclude them from being able to receive the treatment in the future.

Conditions of use to be studied. A sponsor may obtain licensure only for a condition(s) of use for which the reference product is licensed. Sponsors should consider studying a condition of use that would support subsequent extrapolation of data to other conditions of use (e.g., to minimize the cost and duration of studies for other conditions where interchangeability is sought).

Route of administration. If a product is approved for more than one route of administration, sponsors should study the more immunogenic route (e.g., subcutaneous rather than intravenous), as this will better assess how a patient’s immune system response will impact the clinical performance of the product, including changes in safety risk and efficacy.

Non-US-licensed comparator. It is possible to use a non-US-licensed comparator in a switching study, as long as the sponsor supports the choice of comparator by providing adequate data and information to establish a “bridge” between the non-US-licensed comparator and the US-licensed reference product and thereby justify the relevance of the data obtained using the non-US-licensed comparator.

Extrapolation of data. If the proposed product meets the requirements for licensure as an interchangeable product for one condition of use, the sponsor may seek licensure for one or more additional conditions of use for which the reference product is licensed. To support the extrapolation of data, the sponsor needs to provide sufficient scientific justification addressing; for example, the following issues for the tested and extrapolated conditions of use: mechanisms of action; differences in PK, PD, and biodistribution of the product; differences in immunogenicity risk; differences in toxicities; and any other factors that may affect safety or efficacy.

Considerations for developing “presentations” for proposed interchangeable products

A product’s presentation typically includes, in addition to the active therapeutic protein, a container system and potentially a delivery device. A container system refers to the sum of packaging components that together contain and protect the dosage form. A delivery device is used as a medium or carrier for administering a pharmaceutical product to a patient.

A sponsor developing an interchangeable product generally should not seek licensure for a presentation for which the reference product is not licensed. However, a sponsor can discuss other possibilities with FDA.

As applicable, a general description of the presentation should be provided in the chemistry, manufacturing, and controls section of the application, including delivery device constituent part design and development information.

The sponsor should submit data and information supporting the appropriate use and performance testing of the delivery device constituent part of the proposed interchangeable product.

Post-marketing safety monitoring

Post-marketing safety monitoring for interchangeable products should account for the following features:

  • Any particular safety or effectiveness concerns associated with the use of the reference product and its class, the development and clinical experience with the proposed interchangeable product (if already marketed outside the United States), the specific condition of use and patient population, and patient exposure in the interchangeability development program
  • Adequate pharmacovigilance mechanisms.

FDA will require post-market safety surveillance on a risk-adjusted basis (3). FDA may also require a post-marketing study or a clinical trial to evaluate certain safety risks.

Conclusion

Through its guidance, FDA has provided much-needed general principles and factors to consider in determining what kind of data are needed to comply with the 351(k)(4) pathway. FDA has also identified certain specific features to consider in developing and presenting data to FDA when seeking approval for an interchangeable product. Given the complexity of biologic products and the distinct features contributing to the interchangeability assessment for different products, however, sponsors are still facing uncertainties that will need to be addressed on a case-by-case basis. Therefore, as the agency has repeatedly emphasized in its guidance, sponsors should seek early discussions and continue to work closely with FDA at every stage of the process to ensure an effective and efficient process for demonstrating the interchangeability of a chosen biologic product.

References

  1. FDA, Considerations in Demonstrating Interchangeability with a Reference Product, Guidance for Industry (May 9, 2019).
  2. United States Code 42, Chapter 6A, Subchapter II, Part F, subpart 1, Sec. 262, Regulation of biological products. https://www.govinfo.gov/content/pkg/USCODE-2017-title42/html/USCODE-2017-title42-chap6A-subchapII-partF-subpart1-sec262.htm
  3. FDA, Drug and Biologics Safety Surveillance Best Practice Statement, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration (October 2017), https://www.fda.gov/media/106089/download

Co-authored by Yicong Du

Originally Publish by BioPharm International

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions